News

ImmunoCellular Therapeutics or IMUC, a biotechnology company, has signed an agreement with Formatech, a provider of product development and aseptic fill finish manufacturing services, for the development of

Vyteris, a biotechnology company, has initiated a Phase II clinical trial sponsored by its development partner, Ferring Pharmaceuticals. The trial evaluates Vyteris’s smart patch technology for the safety

US-based pharmaceutical company CEL-SCI has entered into an exclusive licensing agreement with Byron Biopharma under which CEL-SCI has granted Byron an exclusive license to market and distribute the

The company’s corporate controller, Len Ross, will become the principal financial and accounting officer. Paul Ashton, president and CEO of pSivida, said: “The company and the board of

Maureen Loftus, president of IBT, said: “IBT Laboratories was one of the first laboratories to develop a commercial pneumococcal assay to measure the concentration of antibodies produced in

Related to this, Biotie-Lundbeck licensing agreement terms have been amended. Under the terms of the amended agreement, Biotie is now eligible for up to E84 million in upfront

GlobalStem will provide full characterization of the cells including sterility and mycoplasma detection testing, karyotyping and assaying for critical markers. CHDI has generated various Huntington’s disease mouse embryonic

Under the terms of the non-exclusive partnership, Home Service will deliver prescription drugs on behalf of Healthscreen to patients electing for a home delivery option during the diabetes

Dr Cohen has spent more than two decades in the healthcare field. Before joining governor Mr Paterson as his chief policy advisor, Dr Cohen served as managing director